Logo image of ALIM

ALIMERA SCIENCES INC (ALIM) Stock Fundamental Analysis

NASDAQ:ALIM - Nasdaq - US0162592028 - Common Stock - Currency: USD

5.54  -0.01 (-0.18%)

After market: 5.54 0 (0%)

Fundamental Rating

4

Taking everything into account, ALIM scores 4 out of 10 in our fundamental rating. ALIM was compared to 198 industry peers in the Pharmaceuticals industry. ALIM has a bad profitability rating. Also its financial health evaluation is rather negative. ALIM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALIM has reported negative net income.
ALIM had a negative operating cash flow in the past year.
In the past 5 years ALIM always reported negative net income.
In the past 5 years ALIM always reported negative operating cash flow.
ALIM Yearly Net Income VS EBIT VS OCF VS FCFALIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

ALIM has a Return On Assets of -10.16%. This is in the better half of the industry: ALIM outperforms 72.82% of its industry peers.
With a decent Return On Equity value of -39.38%, ALIM is doing good in the industry, outperforming 62.05% of the companies in the same industry.
ALIM has a Return On Invested Capital of 0.12%. This is in the better half of the industry: ALIM outperforms 76.92% of its industry peers.
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROIC 0.12%
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALIM Yearly ROA, ROE, ROICALIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

ALIM has a better Operating Margin (0.20%) than 76.92% of its industry peers.
Looking at the Gross Margin, with a value of 86.39%, ALIM belongs to the top of the industry, outperforming 90.26% of the companies in the same industry.
ALIM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.2%
PM (TTM) N/A
GM 86.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
ALIM Yearly Profit, Operating, Gross MarginsALIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALIM is destroying value.
Compared to 1 year ago, ALIM has more shares outstanding
The number of shares outstanding for ALIM has been increased compared to 5 years ago.
Compared to 1 year ago, ALIM has an improved debt to assets ratio.
ALIM Yearly Shares OutstandingALIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALIM Yearly Total Debt VS Total AssetsALIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

ALIM has an Altman-Z score of -1.37. This is a bad value and indicates that ALIM is not financially healthy and even has some risk of bankruptcy.
ALIM's Altman-Z score of -1.37 is in line compared to the rest of the industry. ALIM outperforms 48.21% of its industry peers.
ALIM has a Debt/Equity ratio of 1.80. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.80, ALIM is not doing good in the industry: 78.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Altman-Z -1.37
ROIC/WACC0.01
WACC9.95%
ALIM Yearly LT Debt VS Equity VS FCFALIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

ALIM has a Current Ratio of 2.79. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.79, ALIM perfoms like the industry average, outperforming 45.13% of the companies in the same industry.
ALIM has a Quick Ratio of 2.62. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
ALIM has a Quick ratio of 2.62. This is comparable to the rest of the industry: ALIM outperforms 49.23% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.62
ALIM Yearly Current Assets VS Current LiabilitesALIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

ALIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.66%, which is quite impressive.
ALIM shows a strong growth in Revenue. In the last year, the Revenue has grown by 69.76%.
ALIM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%

3.2 Future

The Earnings Per Share is expected to grow by 22.30% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALIM will show a very strong growth in Revenue. The Revenue will grow by 23.81% on average per year.
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALIM Yearly Revenue VS EstimatesALIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
ALIM Yearly EPS VS EstimatesALIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ALIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 28.59 indicates a quite expensive valuation of ALIM.
77.44% of the companies in the same industry are more expensive than ALIM, based on the Price/Forward Earnings ratio.
ALIM is valuated rather expensively when we compare the Price/Forward Earnings ratio to 20.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 28.59
ALIM Price Earnings VS Forward Price EarningsALIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

ALIM's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ALIM is cheaper than 77.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.66
ALIM Per share dataALIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

ALIM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALIM's earnings are expected to grow with 30.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%

More info and screens

0

5. Dividend

5.1 Amount

ALIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIMERA SCIENCES INC

NASDAQ:ALIM (9/13/2024, 8:00:00 PM)

After market: 5.54 0 (0%)

5.54

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2024-08-06/bmo
Earnings (Next)10-24 2024-10-24/amc
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change0%
Market Cap301.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 28.59
P/S 3.02
P/FCF N/A
P/OCF N/A
P/B 7.77
P/tB N/A
EV/EBITDA 28.66
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.13%
ROICexgc 0.56%
OM 0.2%
PM (TTM) N/A
GM 86.39%
FCFM N/A
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Debt/EBITDA 5.55
Cap/Depr 1.81%
Cap/Sales 0.22%
Interest Coverage 0.03
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.62
Altman-Z -1.37
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A